| Application no. and date | 19708556.6 (espacenet) (Federated) (European Patent Register), 20190308 | | Patent/reg. no. and date | DK/EP 3765452, 20220413 | | Publication date | 20210120 | | Priority no. and date | EP 18161983, 20180315 | | EP pub. no. and date |
EP 3765452 20210120 | | Effective date | | | Applicant/owner | Bayer Pharma Aktiengesellschaft, Müllerstrasse 178
13353 Berlin, DE,
Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1
51373 Leverkusen, DE | | Applicant ref. no. | 1624614 | | Inventor | GÖTZ, Daniel, Martinstr. 46
40223 Düsseldorf, DE,
Egger, Julian, Anton-Küppers-Weg 15
42855 Remscheid, DE,
SOWA, Michal, Kempers Häuschen 10
42109 Wuppertal, DE | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | C07C 233/00 (2006.01) , C07D 401/10 (2006.01) | | Title | FREMGANGSMÅDE TIL FREMSTILLING AF TO 4-{[(2S)-2-{4-[5-CHLOR-2-(1H-1,2,3-TRIAZOL-1-YL)PHENYL]-5-METHOXY-2-OXOPYRIDIN-1(2H)-YL}BUTANOYL]AMINO}-2-FLUORBENZAMIDDERIVATER | | Int. application no. | EP2019055815 | | Int. publication no. | WO2019175043 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
